Vineet Laboratories Limited (NSE:VINEETLAB)

Market Cap	718.89M +135.6%
Revenue (ttm)	560.13M -43.4%
Net Income	-101.39M
EPS	-11.04
Shares Out	19.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,287
Open	38.80
Previous Close	37.43
Day's Range	37.72 - 39.30
52-Week Range	27.96 - 49.99
Beta	0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 15, 2026

About Vineet Laboratories

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl th...

• Industry: Chemicals
• Sector: Materials
• Founded: 2016
• Employees: 57
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VINEETLAB

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 12, 2026

Data Sources Report a data error